EcoDrugPlus

Insulin Receptor B

Ensembl ID : ENSGACG00000010475
Gene Symbol: INSRB
1 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSGACG00000013170
Gene Symbol: IGF1RA
1 Cross references
206 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSGACG00000014729
Gene Symbol: IGF1RB
1 Cross references
204 Possible Orthologues:

Integrin Beta 3a

Ensembl ID : ENSGACG00000008948
Gene Symbol: ITGB3A
1 Cross references
204 Possible Orthologues:

Integrin Beta 3b

Ensembl ID : ENSGACG00000006460
Gene Symbol: ITGB3B
1 Cross references
195 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSGACG00000002051
Gene Symbol: ITGA4
1 Cross references
226 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSGACG00000010880
Gene Symbol: ITGA5
1 Cross references
196 Possible Orthologues:

Integrin Subunit Beta 6

Ensembl ID : ENSGACG00000015179
Gene Symbol: ITGB6
1 Cross references
205 Possible Orthologues:

Integrin Subunit Beta 8

Ensembl ID : ENSGACG00000006439
Gene Symbol: ITGB8
1 Cross references
207 Possible Orthologues:

Integrin, Alpha 5 (Fibronectin Receptor, Alpha Polypeptide)

Ensembl ID : ENSGACG00000010945
Gene Symbol: ITGA5
1 Cross references
206 Possible Orthologues:

Integrin, Alpha V

Ensembl ID : ENSGACG00000000260
Gene Symbol: ITGAV
1 Cross references
238 Possible Orthologues:

Integrin, Beta 1a

Ensembl ID : ENSGACG00000001700
Gene Symbol: ITGB1A
1 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).